Brief: Aptevo Therapeutics Inc Announces Second Complete Remission In Ongoing Apvo436 Phase 1 Clinical Trial
09/11/2020 14:25
Nov 9 (Reuters) - Aptevo Therapeutics Inc APVO.O :
* APTEVO THERAPEUTICS INC - ANNOUNCES SECOND COMPLETE
REMISSION IN
ONGOING APVO436 PHASE 1 CLINICAL TRIAL
* APTEVO THERAPEUTICS INC - SECOND COMPLETE REMISSION
OBSERVED IN
A PATIENT IN COHORT 6
Source: [ID: https://bit.ly/3p5xQ7s]
Further company coverage: APVO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptevo Therapeutics
See all newsBrief: Aptevo Therapeutics - Enters Amendment No. 6 To Rights Agreement On October 23, 2026 - SEC Filing
U.S. STOCKS ON THE MOVE-Principal Financial Group, NetApp
U.S. STOCKS ON THE MOVE-Genesco, Fervo Energy, Tyson Foods
Aptevo Therapeutics reports early data for blood cancer therapy; shares fall
Aptevo Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary